CVKD · Insider Trading
Cadrenal Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by CVKD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-13 | Jeffrey Scott Cole | Chief Operating Officer | A | +150,000 deriv. | — |
| 2026-10-13 | Lee Scott Golden | Director | A | +75,000 deriv. | — |
| 2026-10-13 | John Raymond Murphy | Director | A | +75,000 deriv. | — |
| 2026-10-13 | Quang X Pham | Chairman and CEO | A | +200,000 deriv. | — |
| 2026-10-13 | Glynn Wilson | Director | A | +75,000 deriv. | — |
| 2026-07-01 | Quang X Pham | Chairman and CEO | Sell | −7,400 | −$22.42K |
| 2026-06-26 | Quang X Pham | Chairman, CEO and Interim CFO | Sell | −11,156 | −$33.92K |
| 2026-06-24 | Quang X Pham | Chairman, CEO and Interim CFO | Sell | −11,444 | −$39.83K |
| 2026-06-18 | Quang X Pham | Chairman, CEO and Interim CFO | Sell | −4,126 | −$13.11K |
| 2026-06-15 | Quang X Pham | Chairman, CEO and Interim CFO | Sell | −18,124 | −$70.35K |
| 2026-06-10 | Quang X Pham | Chairman, CEO and Interim CFO | Sell | −22,385 | −$93.29K |
| 2026-06-05 | Quang X Pham | CEO and Chairman | Sell | −8,285 | −$36.21K |
| 2026-06-02 | Quang X Pham | CEO and Chairman | Sell | −652 | −$3.07K |
| 2026-05-29 | Quang X Pham | CEO and Chairman | Sell | −12,763 | −$69.45K |
| 2026-05-26 | Quang X Pham | CEO and Chairman | Sell | −1,165 | −$6.63K |
| 2025-12-31 | Matthew K Szot | Chief Financial Officer | Sell | −9,933 | −$69.23K |
| 2025-12-03 | Lee Scott Golden | Director | A | +5,000 deriv. | — |
| 2025-10-28 | Matthew K Szot | Chief Financial Officer | Sell | −3,600 | −$50.36K |
| 2025-10-28 | Quang X Pham | CEO and Chairman | Sell | −2,444 | −$34.24K |
| 2025-10-14 | Matthew K Szot | Chief Financial Officer | Sell | −3,493 | −$49.01K |
| 2025-10-14 | Quang X Pham | CEO and Chairman | Sell | −3,600 | −$50.71K |
| 2025-10-07 | Matthew K Szot | Chief Financial Officer | Sell | −107 | −$1.50K |
| 2025-10-03 | Quang X Pham | CEO and Chairman | Sell | −500 | −$7.07K |
| 2025-10-01 | Matthew K Szot | Chief Financial Officer | Sell | −1,800 | −$25.18K |
| 2025-10-01 | Quang X Pham | CEO and Chairman | Sell | −1,300 | −$18.21K |
| 2025-09-26 | Quang X Pham | CEO and Chairman | Sell | −9,371 | −$131.78K |
| 2025-09-26 | Matthew K Szot | Chief Financial Officer | Sell | −12,400 | −$174.18K |
| 2025-08-29 | Matthew K Szot | Chief Financial Officer | Sell | −2,000 | −$27.99K |
| 2025-08-29 | Quang X Pham | CEO and Chairman | Sell | −5,029 | −$70.36K |
| 2025-03-24 | Quang X Pham | CEO and Chairman | A | +65,000 deriv. | — |
| 2025-02-06 | James J. Ferguson III | Chief Medical Officer | A | +60,000 deriv. | — |
| 2025-01-24 | Matthew K Szot | Chief Financial Officer | A | +50,000 deriv. | — |
| 2025-01-24 | Steven Zelenkofske | Director | A | +20,000 deriv. | — |
| 2025-01-24 | Quang X Pham | CEO and Chairman | A | +65,000 deriv. | — |
| 2025-01-24 | John Raymond Murphy | Director | A | +20,000 deriv. | — |
| 2025-01-24 | Glynn Wilson | Director | A | +20,000 deriv. | — |
| 2025-01-24 | Jeffrey Scott Cole | Chief Operating Officer | A | +25,000 deriv. | — |
| 2025-01-24 | Robert Lisicki | Director | A | +20,000 deriv. | — |
| 2024-04-10 | Quang X Pham | CEO and Chairman | G | −50,000 | — |
| 2024-04-03 | Jeffrey Scott Cole | Chief Operating Officer | A | +150,000 deriv. | — |
| 2024-02-12 | Quang X Pham | CEO and Chairman | G | −85,000 | — |
| 2024-01-19 | John Raymond Murphy | Director | A | +100,000 deriv. | — |
| 2024-01-19 | Quang X Pham | Chief Executive Officer | A | +150,000 deriv. | — |
| 2024-01-19 | Steven Zelenkofske | Director | A | +100,000 deriv. | — |
| 2024-01-19 | Robert Lisicki | Director | A | +50,000 deriv. | — |
| 2024-01-19 | Glynn Wilson | Director | A | +70,000 deriv. | — |
| 2024-01-19 | Douglas W Losordo | Chief Medical Officer | A | +150,000 deriv. | — |
| 2024-01-19 | Matthew K Szot | Chief Financial Officer | A | +250,000 deriv. | — |
| 2023-10-06 | John Raymond Murphy | Director | Buy | +20,000 | +$13.97K |
| 2023-09-06 | Quang X Pham | CEO and Chairman | Buy | +40,000 | +$36.19K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Quang X Pham | Chairman and CEO | 298,589 | $271.72K |
| John Raymond Murphy | Director | 40,986 | $37.30K |
| Glynn Wilson | Director | 3,333 | $3.03K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CVKD quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.